4.6 Review

Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease

Journal

WORLD JOURNAL OF GASTROENTEROLOGY
Volume 26, Issue 35, Pages 5362-5374

Publisher

BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v26.i35.5362

Keywords

Inflammatory bowel disease; Osteoporosis; Systematic review; Epidemiology; Bone mineral density

Ask authors/readers for more resources

BACKGROUND The inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC) are chronic, immune-mediated disorders of the digestive tract. IBD is considered to be a risk factor for developing osteoporosis; however current literature on this matter is inconsistent. AIM To assess prevalence and development of osteoporosis and low bone mineral density (BMD), and its risk factors, in IBD patients. METHODS Systematic review of population-based studies. Studies were identified by electronic (January 2018) and manual searches (May 2018). Databases searched included EMBASE and PubMed and abstracts from 2014-2018 presented at the United European Gastroenterology Week, the European Crohn's and Colitis Organisation congress, and Digestive Disease Week were screened. Studies were eligible for inclusion if they investigated either the prevalence of osteoporosis or osteopenia and/or risk factors for osteoporosis or low BMD in IBD patients. Studies on children under the age of 18 were excluded. Only population-based studies were included. All risk factors for osteoporosis and low BMD investigated in any included article were considered. Study quality and the possibility of bias were analysed using the Newcastle-Ottawa scale. RESULTS Twelve studies including 3661 IBD patients and 12789 healthy controls were included. Prevalence of osteoporosis varied between 4%-9% in studies including both CD and UC patients; 2%-9% in studies including UC patients, and 7%-15% in studies including CD patients. Among healthy controls, prevalence of osteoporosis was 3% and 10% in two studies. CD diagnosis, lower body mass index (BMI), and lower body weight were risk factors associated with osteoporosis or low BMD. Findings regarding gender showed inconsistent results. CD patients had an increased risk for osteoporosis or low BMD over time, while UC patients did not. Increased age was associated with decreased BMD, and there was a positive association between weight and BMI and BMD over time. Great heterogeneity was found in the included studies in terms of study methodologies, definitions and the assessment of osteoporosis, and only a small number of population-based studies was available. CONCLUSION This systematic review found a possible increase of prevalence of osteoporosis in CD cohorts when compared to UC and cohorts including both disease types. Lower weight and lower BMI were predictors of osteoporosis or low BMD in IBD patients. The results varied considerably between studies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

The Impact of Periodontitis on Inflammatory Bowel Disease Activity

Gorm Roager Madsen, Kristina Bertl, Nikolaos Pandis, Andreas Stavropoulos, Johan Burisch

Summary: In this questionnaire-based study, periodontitis was found to be significantly associated with increased IBD disease activity in the last 12 months, as well as increased IBD disability.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Risk Factors for Developing Inflammatory Bowel Disease Within and Across Families with a Family History of IBD

Joana Torres, Catarina Gomes, Camilla Jensen, Manasi Agrawal, Francisco Morao, Tine Jess, Jean-Frederic Colombel, Kristine H. Allin, Johan Burisch

Summary: In this study, risk factors for unaffected first-degree relatives (FDRs) of inflammatory bowel disease (IBD) patients to develop the disease were identified. These findings provide an opportunity for counseling IBD relatives.

JOURNAL OF CROHNS & COLITIS (2023)

Article Gastroenterology & Hepatology

Disease course and treatment outcomes of Crohn's disease patients with early or late surgery-A Danish nationwide cohort study from 1997 to 2015

M. Z. Sarikaya, M. Zhao, B. Lo, F. Bendtsen, J. Burisch

Summary: This nationwide cohort study aimed to investigate the disease course in Crohn's disease patients who underwent early and late major abdominal surgery. The study found that patients who underwent surgery within 29 days of diagnosis had a lower cumulative risk of re-operation and a shorter cumulative exposure to immunomodulators in the initial years after surgery.

DIGESTIVE AND LIVER DISEASE (2023)

Article Gastroenterology & Hepatology

Development of a Core Outcome Set for Real-world Data in Inflammatory Bowel Disease: A European Crohn's and Colitis Organisation [ECCO] Position Paper

Jurij Hanzel, Peter Bossuyt, Valerie Pittet, Mark Samaan, Monika Tripathi, Wladyslawa Czuber-Dochan, Johan Burisch, Salvatore Leone, Roberto Saldana, Filip Baert, Uri Kopylov, Susanna Jaghult, Michel Adamina, Naila Arebi, Krisztina Gecse

Summary: This study aimed to develop a core outcome set for real-world studies in adult patients with inflammatory bowel disease (IBD). Candidate outcomes and outcome measures were identified through a systematic review and a modified Delphi consensus process. The international panel agreed on the final core outcome set, which will facilitate the synthesis and generation of real-world evidence.

JOURNAL OF CROHNS & COLITIS (2023)

Article Gastroenterology & Hepatology

ECCO Guidelines on Inflammatory Bowel Disease and Malignancies

Hannah Gordon, Livia Biancone, Gionata Fiorino, Konstantinos H. Katsanos, Uri Kopylov, Eman Al Sulais, Jordan E. Axelrad, Karthiha Balendran, Johan Burisch, Lissy de Ridder, Lauranne Derikx, Pierre Ellul, Thomas Greuter, Marietta Iacucci, Caroline Di Jiang, Christina Kapizioni, Konstantinos Karmiris, Julien Kirchgesner, David Laharie, Triana Lobaton, Tamas Molnar, Nurulamin M. Noor, Rohit Rao, Simone Saibeni, Michael Scharl, Stephan R. Vavricka, Tim Raine

JOURNAL OF CROHNS & COLITIS (2023)

Review Gastroenterology & Hepatology

Systematic Review with Meta-analysis: The Impact of Cancer Treatments on the Disease Activity of Inflammatory Bowel Diseases

Sigrun Grimsdottir, Mohamed Attauabi, Emilie Kristine Dahl, Johan Burisch, Jakob Benedict Seidelin

Summary: A systematic review found that a high proportion of patients with inflammatory bowel disease (IBD) experience flares following cancer treatment, with an increased risk of gastrointestinal toxicity in IBD patients receiving immune checkpoint inhibitor treatment. However, current studies suggest that IBD flares induced by cancer therapy can be managed and should not prevent appropriate cancer treatments.

JOURNAL OF CROHNS & COLITIS (2023)

Editorial Material Gastroenterology & Hepatology

Is hypertension an extra-intestinal manifestation of inflammatory bowel disease?

Johan Burisch

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2023)

Article Psychology, Clinical

Exploring the Impact of Covid-19-Related Perceptions on Psychological Distress and Quality of Life in an International Gastrointestinal Cohort Over Time Guided by the Common Sense Model

Simon R. Knowles, Stephan P. Moller, Andreas Stengel, Antonina Mikocka-Walus, Nuno Ferreira, Ines A. Trindade, Anna Mokrowiecka, Johan Burisch, Manuel Barreiro-de Acosta, Charles N. Bernstein, Bobby Lo, David Skvarc

Summary: The aim of this longitudinal study was to examine changes in COVID-19 and illness-related perceptions, gastrointestinal symptoms, coping, catastrophising, psychological distress, and QoL during the COVID-19 pandemic. A total of 831 adults with a gastrointestinal condition completed an online questionnaire at baseline (May-October 2020). Of those, 270 (32.5%) participants (85.2% female, mean age = 47.3 years) provided follow-up data (March-May 2021). The results showed that gastrointestinal symptoms and COVID-19 perceptions at follow-up were strongly predicted by their baseline values, while illness perceptions were predicted by baseline gastrointestinal symptoms. Cross-lagged relationships indicated a reciprocal relationship between gastrointestinal symptoms and psychological distress. Moreover, gastrointestinal symptoms had substantial predictive utility, strongly predicting future gastrointestinal symptoms, and to a lesser extent, more negative illness perceptions, greater psychological distress, and greater use of adaptive coping strategies across time.

JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS (2023)

Editorial Material Gastroenterology & Hepatology

Editorial: Why are patients with Crohn's disease still treated with 5-aminosalicylates?

Johan Burisch

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

Impact of Vedolizumab on Extraintestinal Manifestations in Inflammatory Bowel Disease: Results From a Descriptive, Retrospective, Real-world Study

Uri Kopylov, Johan Burisch, Shomron Ben-Horin, Fiona Braegger, Alonso Fernandez-Nistal, Nuria Lara, Henriette Sophie Heinrich, Stephan R. Vavricka

Summary: This study demonstrated that vedolizumab treatment resulted in improvements in extraintestinal manifestations in patients with IBD, showing its effectiveness and good safety profile.

INFLAMMATORY BOWEL DISEASES (2023)

Letter Dermatology

Characteristics of patients with hidradenitis suppurativa and concomitant inflammatory bowel disease

Valdemar W. Nielsen, Astrid-Helene R. Jorgensen, Yiqiu Yao, Hans C. Ring, Mohamed Attauabi, Gorm R. Madsen, Johan Burisch, Simon F. Thomsen

INTERNATIONAL JOURNAL OF DERMATOLOGY (2023)

Article Gastroenterology & Hepatology

Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020

Kristoffer Jarlov Jensen, Camilla Bjorn Jensen, Christina Wennerstroem, Johan Burisch, Janne Petersen

Summary: This study aimed to characterize the drug utilization and switch patterns of biological treatment for ulcerative colitis (UC) and Crohn's disease (CD). The majority of UC and CD patients initiating biologic therapy chose infliximab as their first-line treatment. Adalimumab had a higher risk of treatment discontinuation compared to infliximab, while vedolizumab had a lower risk of discontinuation for UC patients.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2023)

Review Gastroenterology & Hepatology

Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysis

Sofie Ingdam Halkjaer, Bobby Lo, Frederik Cold, Alice Hojer Christensen, Savanne Holster, Julia Konig, Robert Jan Brummer, Olga C. Aroniadis, Perttu Lahtinen, Tom Holvoet, Lise Lotte Gluud, Andreas Munk Petersen

Summary: Fecal microbiota transplantation (FMT) has been suggested as a treatment for irritable bowel syndrome (IBS), but the efficacy and safety of FMT for IBS remain unclear. This review found insufficient evidence to support or refute the use of FMT for IBS. Larger trials are needed to further evaluate its effectiveness.

WORLD JOURNAL OF GASTROENTEROLOGY (2023)

Review Medicine, General & Internal

Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis

Mohamed Attauabi, Emilie Kristine Dahl, Johan Burisch, John Gubatan, Ole Haagen Nielsen, Jakob Benedict Seidelin

Summary: This study compared the onset of efficacy of biological therapies and small molecules in patients with moderate-to-severe ulcerative colitis (UC). The results showed that upadacitinib had significantly better clinical response and clinical remission at two weeks compared to other agents, while ustekinumab and ozanimod had the lowest efficacy.

ECLINICALMEDICINE (2023)

Article Dentistry, Oral Surgery & Medicine

Health-related quality of life aspects of the 'Periodontitis prevalence in ulcerative colitis and Crohn's disease' (PPCC) cohort

Kristina Bertl, Georgios Tsakos, Nikolaos Pandis, Anna Bogren, Johan Burisch, Andreas Stavropoulos

Summary: This study is the first to find that oral health problems are associated with the disease-specific quality of life (QoL) of inflammatory bowel disease (IBD) patients, and vice versa. This emphasizes the potential advantages of including dental professionals in the multi-disciplinary treatment teams of IBD patients.

JOURNAL OF CLINICAL PERIODONTOLOGY (2023)

No Data Available